Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
ANKRD44 intronic transcript 1 (ANKRD44-IT1)
- Target
- ANKRD44-IT1
- Molecular classification
- Long noncoding RNA (lncRNA), Intronic transcript, Putative micropeptide-encoding lncRNA
01
Overview
ANKRD44 intronic transcript 1 (ANKRD44-IT1) is a long noncoding RNA (lncRNA) located within the intronic region of the ANKRD44 gene and is found in the cytoplasm of human cells[1][3][4]. It is identified as upregulated in osteosarcoma tumor samples compared to normal bone[1][2]. Bioinformatic analysis predicts that ANKRD44-IT1 may encode micropeptides, which is uncommon among lncRNAs[1]. Functional studies specifically characterizing ANKRD44-IT1 are lacking. However, it has been computationally shown to interact with VEGFC and ADCYAP1R1, genes crucial for cancer cell mobility and angiogenesis, suggesting a potential but as-yet unconfirmed role in tumor progression or metastasis. Despite its differential expression in cancer, ANKRD44-IT1 is not established as a therapeutic target, and its biological and clinical significance remain to be elucidated[1][2][3][4].
- Other names
- ANKRD44 intronic transcript 1 (non-protein coding)ANKRD44-IT1
02
Mechanism of action
Not established; no drugs are known to act through this lncRNA. Putative mechanism in cancer may involve interaction with genes such as VEGFC (vascular endothelial growth factor-C) and ADCYAP1R1 (ADCYAP receptor type I) through RNA-mediated gene regulation
03
Biological functions
Poorly characterized; suggested functions include possible involvement in cancer biology (notably osteosarcoma) where it may encode micropeptides and reside in the cytoplasmPutative regulator of interactions with protein-coding genes and genes involved in tumor biology through RNA-RNA or lncRNA-protein interactions
04
Disease associations
CancerEspecially implicated in osteosarcoma due to upregulation in tumor vs. normal tissueNote: direct functional or mechanistic disease roles remain minimally defined or speculative.
05
Safety considerations
None reported (little is known about therapeutic targeting or manipulation of this RNA; thus, no established safety profile[1][2])
06
Interacting drugs
None known (no drugs have been reported to directly interact with or target ANKRD44-IT1; no evidence from available data[1][2][3][4])
07
Biomarkers
None definitively established; ANKRD44-IT1 expression may serve as a potential biomarker of osteosarcoma, though this is investigational and not clinically validated
Beyond the preview
Go deeper on ANKRD44 intronic transcript 1 (ANKRD44-IT1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ANKRD44 intronic transcript 1 (ANKRD44-IT1).